annb0t
Top 20
MELBOURNE, Australia, July 18, 2024 /PRNewswire/ --Â Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024). (PRNewsfoto/Telix Pharmaceuticals Limited)
Q2 2024 Financial Performance and Guidance Upgrade
The Company reports unaudited total revenue of approximately US$124M[1] (AU$189M) primarily generated from sales of Telix's prostate cancer imaging product Illuccix®. This...
>>> Read more: Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
Q2 2024 Financial Performance and Guidance Upgrade
The Company reports unaudited total revenue of approximately US$124M[1] (AU$189M) primarily generated from sales of Telix's prostate cancer imaging product Illuccix®. This...
>>> Read more: Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
